Structural and functional complementation of an inactive Bcl-2 mutant by Bax truncation

Area of Science:

• Molecular Biology
• Cell Biology
• Biochemistry

Background:

• Proteins in the B-cell lymphoma 2 (Bcl-2) family control programmed cell death.
• Death-inhibiting proteins Bcl-2 and Bcl-xL bind to the death-promoting protein Bax.
• Mutations in Bcl-2 and Bcl-xL can abolish their biological activity and Bax binding.

Purpose of the Study:

• To investigate the structural basis of heterodimer formation between Bcl-2 family proteins.
• To identify Bax mutants that can bind to inactive Bcl-2 and Bcl-xL mutants.
• To understand how conformational changes in Bax affect its interactions with other Bcl-2 family members.

Main Methods:

• Yeast two-hybrid assay to screen for Bax mutants.
• Site-directed mutagenesis of Bcl-2 and Bcl-xL proteins.
• Analysis of protein-protein interactions and apoptosis induction.

Main Results:

• Inactive Bcl-2(G145A) and Bcl-xL(G138A) mutants bind to C-terminally truncated Bax molecules containing the BH3 domain.
• Full-length Bax mutants that bind to inactive Bcl-2/Bcl-xL were identified, indicating the BH3 domain is critical for binding.
• Inactive Bcl-2(G145A) blocked apoptosis induced by truncated Bax but not wild-type Bax.

Conclusions:

• Conformational constraints in full-length Bax regulate its binding to other Bcl-2 family members.
• The BH3 domain of Bax is essential for binding to inactive Bcl-2 and Bcl-xL.
• Direct binding to pro-apoptotic proteins can mediate cell protection, offering a novel therapeutic strategy.